SOC Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

Related Keywords

United States ,Catherinec Coombs ,Angelag Fleischmann ,Naveen Pemmaraju ,Joshuaf Zeidner ,International Consensus Classification ,School Of Medicine ,Division Of Hematology ,Department Of Medicine ,World Health Organization ,University Of California Irvine ,Onclive Institutional Perspectives ,California Irvine ,New England Journal ,Chapel Hill ,International Consensus ,Bcl2 Inhibitors ,Btk Inhibitors ,Chronic Lymphocytic Leukemia ,Cll ,D ,Myelofibrosis ,Aml ,Acute Myeloid Leukemia ,Hematologic Malignancies ,Combination Therapy ,Quizartinib ,Ruxolitinib ,2023 Ash Annual Meeting ,